UP!

SRCL $49.87

SRCL target price
49.87
0
0
Stericycle
Type
Public
Traded as
  • NASDAQ: SRCL
  • S&P 500 component
Industry Services - Compliant Regulated Waste Disposal, Secure Information Destruction Services, Recall Services, Sustainability Services, Communications Services
Founded 1989
Headquarters Lake Forest, Illinois, U.S.
Key people
Charlie Alutto, President, Chief Executive Officer
Dan Ginnetti, Chief Financial Officer
Revenue
  • Increase US$ 2.142,807 billion (2013)
  • Increase US$ 1.913,149 billion (2012)
Operating income
  • Increase US$ 535.619 million(2013)
  • Increase US$ 468.836 million(2012)
Net income
  • Increase US$ 311.372 million(2013)
  • Increase US$ 267.996 million (2012)
Total assets
  • Increase US$ 3,882.797 million (2013)
  • Increase US$ 3,546.738 million (2012)
Total equity
  • Increase US$ 1,767.538 million (2013)
  • Increase US$ 1,557.323 million (2012)
Website www.stericycle.com

Stericycle is a compliance company that specializes in collecting and disposing regulated substances, such as medical waste and sharps, pharmaceuticals, hazardous waste, and providing services for recalled and expired goods. It also provides related education and training services, and patient communication services. The company was founded in 1989 and is headquartered in Lake Forest, Illinois, with many more bases of operation around the world, including toxic waste incinerators in Utah and North Carolina.

Stericycle has been harshly criticized by residents living near their incinerators and environmentalists across the globe. Currently, Stericycle is being investigated by the state of Utah for burning hazardous, radioactive waste above legal levels at their North Salt Lake location. The investigations also are in response to Stericycle's falsification of records to hide the illegal quantity burning near Foxboro Elementary in North Salt Lake.

Stericycle, Inc., together with its subsidiaries, offers regulated waste management services, sharps disposal containers to reduce the risk of needlesticks, healthcare compliance services, pharmaceutical disposal, and regulated returns management services for expired or recalled products through incineration processes.

The company serves healthcare facilities such as hospitals, blood banks, pharmaceutical manufacturers,. Stericycle also serves myriad small businesses, which include outpatient clinics, medical and dental offices, abortion clinics, veterinary and animal hospitals, funeral homes, home healthcare agencies, body art studios, and long-term and sub-acute care facilities. Medical device manufacturers, consumer goods manufacturers, and retailers are also key customers.

Stericycle was founded in 1989 as a regulated medical waste company. It became a publicly traded company in 1996. In the late 80's Troy had a vision. He saw a need in the industry and jumped on it.

In 1999, Stericycle began offering safety and compliance training services with the launch of its Stericycle Steri-Safe OSHA Compliance program.

Stericycle's hospital offerings grew in 2003 when it acquired Bio Systems. Today, Stericycle Sharps Management Service with Bio Systems containers is the US leader in reusable sharps container management service.

The company’s pharmaceutical waste programs provide disposal of unused or expired wastes in hospitals, healthcare practices, and pharmacies.

To help hospitals manage their waste streams and drive recycling efforts, Stericycle began to offer Stericycle Integrated Waste Stream Solutions in 2009.

In 2010, Stericycle expanded its service offering again to include patient notification services with the acquisition of NotifyMD. Several other acquisitions followed, giving Stericycle a leadership position in telephone support services for physician offices. Serving customers across the United States, the NotifyMD team provides a breadth of services designed to improve office productivity and communication with patients.

In 2014, Stericycle acquired PSC Environmental Services LLC in a deal worth $275 million to form Stericycle Environmental Solutions. This acquisition further reinforced Stericycle's position in the waste management industry, with specific expansion in hazardous waste management.

In 2015, Stericycle acquired Shred-it International in a deal worth $2.3 billion.

The company’s international business began in 1997 with a joint venture in Mexico.

Since then, Stericycle has created services, tools and resources for healthcare professionals not only in the United States and Mexico, but also in Argentina, Brazil, Canada, Chile, Ireland, Japan, Portugal, Puerto Rico, Romania, Spain, and the United Kingdom. In the UK the subsidiary is called SRCL. In 2017 it started litigation against NHS England for £2.5 million for the non-payment of services for healthcare waste.

Beyond services related to healthcare wastes, in some markets the company has expanded its offerings to include management of certain hazardous wastes as well as patient transport and medical courier services.

Stericycle's medical waste incinerator located in North Salt Lake, Utah has been a topic of hot debate in the community. In September 2013, Erin Brockovich joined in with Utah residents in their call for Stericycle to discontinue their business in the area. Brockovich's visit was spurred by a violation notice from the Utah Division of Air Quality to Stericycle for excessive emissions above legal limits, and manipulating their reporting to show lower amounts of Mercury, Dioxins, and other potentially harmful chemicals emitted through burning medical waste.

The violations in 2013 were followed by criminal investigations at the order of Utah Governor Gary Herbert. Investigations by California's Soil Water Air Protection Enterprise, or SWAPE, in connection with Ms. Brockovich, discovered Dioxin in homes near the incinerator at levels 16x higher than what is considered "safe".

As of December 1, 2014, Stericycle and the Utah Division of Air Quality reached an agreement acknowledging no wrongdoing, though the settlement does require Stericycle to relocate approximately 40 miles to the west of the incinerator's current location in North Salt Lake. The settlement also calls for Stericycle to pay a $2.3 million fine, half of which is forgivable if the move happens within 3 years.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-10-31 Future report Set alerts
Q2 2022 2022-08-05 0.48 0.48
Q1 2022 2022-04-28 0.00 0.00
Q4 2021 2022-02-24 0.38 0.38
Q3 2021 2021-11-02 0.44 0.44
Q2 2021 2021-08-06 0.67 0.67
Q1 2021 2021-04-29 0.71 0.71
Q4 2020 2021-02-25 0.59 0.59
Q3 2020 2020-11-05 0.00 0.00
Q2 2020 2020-08-06 0.46 -0.05

Ratings

2016-05-26 Lower Price Target Imperial Capital In to In-Line $100.00 to $95.00
2016-05-26 Reiterated Rating RBC Capital Sell
2016-05-26 Reiterated Rating Royal Bank Of Canada Sell
2016-05-17 Reiterated Rating Jefferies Group Buy $140.00
2016-05-09 Lower Price Target Wedbush Neutral $112.00 to $100.00
2016-05-02 Lower Price Target Wedbush Neutral $128.00 to $112.00
2016-04-30 Reiterated Rating Oppenheimer Hold
2016-04-30 Reiterated Rating Imperial Capital Hold
2016-04-30 Reiterated Rating Oppenheimer Holdings Inc. Hold
2016-04-29 Lower Price Target Imperial Capital In to line $115.00 to $95.00
2016-04-29 Upgrade Wellington Shields Hold to Accumulate
2016-04-29 Downgrade Stifel Nicolaus Buy to Hold
2016-04-29 Downgrade Raymond James Outperform to Market Perform
2016-04-29 Downgrade RBC Capital Sector Perform to Underperform $119.00 to $96.00
2016-04-29 Downgrade Raymond James Financial Inc. Outperform to Market Perform
2016-04-18 Reiterated Rating Stifel Nicolaus Buy $145.00
2016-03-23 Boost Price Target Goldman Sachs $127.00
2016-03-23 Boost Price Target Goldman Sachs Group Inc. $127.00
2016-03-22 Initiated Coverage Sterne Agee CRT Buy $151.00
2016-02-23 Reiterated Rating Jefferies Group Buy $146.00
2016-02-08 Lower Price Target RBC Capital Sector Perform $120.00 to $119.00
2016-02-08 Lower Price Target Imperial Capital In to In-Line $135.00 to $115.00
2016-02-05 Lower Price Target Macquarie Outperform $155.00 to $145.00
2016-02-05 Lower Price Target Robert W. Baird Neutral $130.00 to $129.00
2016-02-05 Lower Price Target Goldman Sachs Neutral $128.00 to $124.00
2015-12-16 Lower Price Target Jefferies Group Buy $155.00 to $146.00
2015-12-08 Reiterated Rating Wedbush Neutral $135.00 to $121.00
2015-11-30 Reiterated Rating RBC Capital Sector Perform $122.00 to $119.00
2015-11-10 Lower Price Target Wedbush Neutral $155.00 to $135.00
2015-10-26 Lower Price Target Imperial Capital In to line $150.00 to $135.00
2015-10-23 Reiterated Rating Imperial Capital Hold $150.00 to $135.00
2015-10-23 Lower Price Target Wedbush Neutral $160.00 to $155.00
2015-10-23 Downgrade Oppenheimer Outperform to Market Perform
2015-10-23 Lower Price Target Stifel Nicolaus Buy $160.00 to $145.00
2015-10-23 Lower Price Target RBC Capital Sector Perform $147.00 to $122.00
2015-10-23 Downgrade Robert W. Baird Outperform to Neutral $145.00 to $130.00
2015-10-09 Reiterated Rating William Blair Buy
2015-10-08 Boost Price Target Wedbush Neutral $143.00 to $160.00
2015-09-08 Upgrade Raymond James Market Perform to Outperform
2015-05-22 Boost Price Target Stifel Nicolaus Buy $156.00 to $160.00
2015-03-25 Initiated Coverage Imperial Capital In to In-Line $150.00
2015-03-12 Boost Price Target RBC Capital Sector Perform $128.00 to $131.00
2015-01-08 Initiated Coverage Macquarie Outperform
2014-12-30 Initiated Coverage Macquarie Outperform
2014-12-19 Initiated Coverage Macquarie Outperform $155.00
2014-11-21 Boost Price Target Oppenheimer Outperform $130.00 to $137.00
2014-10-24 Boost Price Target Oppenheimer Outperform $128.00 to $130.00
2014-09-03 Downgrade Goldman Sachs Buy to Neutral
2014-07-25 Reiterated Rating Jefferies Group Buy $127.00 to $136.00
2014-06-13 Upgrade Robert W. Baird Neutral to Outperform $128.00 to $140.00
2014-04-28 Boost Price Target Barrington Research Outperform $129.00 to $131.00
2014-04-11 Lower Price Target Goldman Sachs Buy $131.00 to $129.00
2014-01-13 Boost Price Target Wunderlich Buy $125.00 to $140.00
2014-01-13 Initiated Coverage Credit Suisse Outperform $140.00
2014-01-10 Initiated Coverage RBC Capital Strong-Buy to Sector Perform $124.00
2013-10-24 Boost Price Target Robert W. Baird Neutral $126.00 to $128.00
2013-10-24 Reiterated Rating Stifel Nicolaus Buy $123.00 to $138.00
2013-10-24 Downgrade Raymond James Outperform to Market Perform $124.00
2013-09-22 Boost Price Target Wunderlich Buy $123.00 to $125.00
2013-03-25 Reiterated Oppenheimer Outperform $105 to $115
2012-07-11 Initiated Barrington Research Outperform $108
2011-04-28 Downgrade Robert W. Baird Outperform to Neutral $88 to $95
2011-04-19 Reiterated Wedbush Outperform $94 to $100
2011-01-19 Reiterated Wedbush Neutral $69 to $74
2010-10-25 Reiterated Wedbush Neutral $58 to $69
2010-09-30 Reiterated Wunderlich Hold $50 to $63
2010-07-09 Initiated Jefferies Buy
2010-05-27 Upgrade Wunderlich Sell to Hold $42 to $50
2016-05-26 Lower Price Target Imperial Capital In to In-Line $100.00 to $95.00
2016-05-26 Reiterated Rating RBC Capital Sell
2016-05-26 Reiterated Rating Royal Bank Of Canada Sell
2016-05-17 Reiterated Rating Jefferies Group Buy $140.00
2016-05-09 Lower Price Target Wedbush Neutral $112.00 to $100.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
SCHULER JACK W 0.74%  (626142) AXDX / BIOL / GTXI / HNSN / MBLX / MDT / QDEL / SRCL / VRML /
MILLER MARK C Chairman & CEO 0.22%  (188863) AXDX / SRCL /
PATIENCE JOHN 0.18%  (149629) AXDX / SRCL /
TEN BRINK FRANK JM CFO 0.03%  (27488) AXDX / SRCL /
Collins Michael J President RMS 0.01%  (9154) SRCL /
HALL WILLIAM K 0.01%  (9000) ATU / GWW / RELY / SRCL /
Ginnetti Daniel Chief Financial Officer 0.01%  (6746) SRCL /
KOGLER RICHARD T EVP & COO 0.01%  (5771) SRCL /
ALUTTO CHARLES A President, Stericycle USA 0.01%  (4843) SRCL /
Arnold Brent President, USA/Canada 0.01%  (4254) SRCL /